AXL and lung carcinoma: These results suggest that treatment during the initial phase with a combination of osimertinib and an AXL inhibitor may prevent the development of intrinsic resistance to osimertinib and the emergence of drug-tolerant cells in EGFR-mutated lung cancer overexpressing AXL.